Polar Asset Management Partners Inc. Takes Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Polar Asset Management Partners Inc. bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 185,245 shares of the medical instruments supplier's stock, valued at approximately $1,697,000. Polar Asset Management Partners Inc. owned about 0.46% of AngioDynamics as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ANGO. SBI Securities Co. Ltd. bought a new stake in AngioDynamics during the fourth quarter worth approximately $28,000. R Squared Ltd bought a new stake in AngioDynamics in the fourth quarter valued at about $49,000. US Bancorp DE lifted its position in shares of AngioDynamics by 1,938.0% during the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock worth $61,000 after buying an additional 6,376 shares during the period. Quinn Opportunity Partners LLC acquired a new stake in shares of AngioDynamics in the 4th quarter valued at $92,000. Finally, ProShare Advisors LLC acquired a new position in shares of AngioDynamics in the 4th quarter worth approximately $100,000. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Price Performance

Shares of NASDAQ ANGO traded up $0.20 during midday trading on Friday, hitting $10.20. The stock had a trading volume of 911,545 shares, compared to its average volume of 559,515. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50. The firm has a market cap of $414.19 million, a P/E ratio of -1.81 and a beta of 0.58. The company's 50-day simple moving average is $9.47 and its 200 day simple moving average is $9.55.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. The firm's revenue for the quarter was down 4.3% on a year-over-year basis. Equities analysts expect that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $16.00 price objective (up previously from $15.00) on shares of AngioDynamics in a report on Monday, April 7th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.